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S U M M A R Y
Objectives: The objectives of the study were to assess the utility of dried blood spots (DBS) for the
detection of cytomegalovirus (CMV) antibody and viremia in a resource-poor setting, to study the
prevalence of CMV antibody and viremia in HIV-infected patients with access to antiretroviral therapy
(ART) in Tanzania, and to relate CMV viremia to outcome.
Methods: DBS were prepared from 168 ART-naı¨ve patients at baseline. Demographic, clinical, and
laboratory data were obtained from patient records. CMV antibody was analyzed by chemiluminescent
microparticle immunoassay and viremia by quantitative PCR.
Results: All patients were CMV-seropositive. At baseline 38 (22.6%) had detectable CMV viremia and 14
(8.3%) had a CMV viral load 200 copies/ml. In 135 patients available for follow-up, CMV 200 copies/ml
was an independent risk factor for death with a hazard ratio of 5.0 (95% conﬁdence interval 2.1–11.9)
after adjusting for confounders. Symptoms compatible with CMV disease were common with viremia
200 copies/ml and CD4+ T cell counts <100 cells/mm3, but conﬁrmatory diagnostic procedures were
unavailable.
Conclusions: DBS are suitable for the detection of CMV antibody and viremia in HIV patients in resource-
poor areas. CMV viremia was frequent and associated with an increased risk of death. Improved
diagnosis and treatment of CMV may improve the prognosis for HIV-infected patients in developing
countries and should be addressed in future studies.
 2012 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Cytomegalovirus (CMV) is a cause of chronic infection that is
controlled by effective cellular immunity in the immunocompe-
tent host. However, CMV may cause serious end-organ disease in
persons with an immunodeﬁciency, as in advanced HIV infection.1
Before effective antiretroviral therapy (ART) became standard of
care, CMV disease was a common cause of morbidity and mortality
in patients with HIV in developed countries.2 However, a dramatic
decrease in the incidence of CMV disease was observed after the
introduction of ART.3–5* Corresponding author. Tel.: +47 22118080; fax: +47 23027704.
E-mail address: arne.brantsater@medisin.uio.no (A.B. Brantsæter).
1201-9712/$36.00 – see front matter  2012 International Society for Infectious Disea
http://dx.doi.org/10.1016/j.ijid.2012.08.003CMV seroprevalence increases with lower socioeconomic
status, and in developed countries more than 50% of the adult
population harbor CMV.6 Studies from Africa have generally found
high seroprevalence, mostly above 80%,7–12 but few studies have
addressed CMV-related morbidity and mortality on this continent.
Due to diagnostic limitations, CMV disease is likely to be
underreported, as has been suggested for Asian patients.13–15
Several studies from developed countries have conﬁrmed that
CMV viremia is an independent risk factor for progression of HIV
infection and death,2,16–21 but few studies from developing
countries have addressed this issue. Although the rollout of ART
has been a priority in resource-poor settings, the diagnosis and
treatment of complications of CMV co-infection is a challenge that
has received little attention.
We have recently shown that dried blood spots (DBS) have
utility for the detection of HIV viremia.22,23 DBS have been used forses. Published by Elsevier Ltd. All rights reserved.
Figure 1. Scatter plot of CMV viremia in dried blood spots (DBS) and plasma in nine
viremic patients. Plasma and DBS samples were prepared in parallel. The line
represents the identity line, on which all results would lie if the detected CMV viral
load in DBS and plasma were identical.
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studies have used DBS to study CMV infection and viremia in
patients with HIV. The aims of the present study were to test the
utility of DBS for the detection of CMV antibody and viremia in a
resource-poor setting, to characterize the prevalence of CMV
infection and viremia in ART-naı¨ve HIV-infected patients in rural
Tanzania, and to relate CMV viremia to clinical outcome.
2. Methods
2.1. Study population in Tanzania
This study included 168 HIV-infected ART-naı¨ve patients
presenting to Haydom Lutheran Hospital in rural northern Tanzania.
DBS were prepared from patients attending the clinic between
February 18, 2008 and February 2, 2010. Baseline data were obtained
from the patient ﬁles, including age, gender, pregnancy, height,
weight, CD4+ T cell and CD8+ T cell counts, hemoglobin, and World
Health Organization (WHO) stage. Laboratory and clinical data from
the dates nearest to the days of production of the DBS were used. If
this was more than 30 days from these dates, the average of the two
results on days before and after production of DBS were used, if
available. In addition, clinical information regarding chronic
diarrhea and fever at the time of enrolment into the HIV program
was recorded. After baseline, the following data were collected:
CD4+ T cell counts (at approximately 3-month intervals), date of
start of ART, death, and loss to follow-up.
2.2. Preparation of DBS
Whole blood from an ethylenediaminetetraacetic acid (EDTA)
plasma preparation tube (Becton Dickinson, Franklin Lakes, NJ,
USA) was applied to a Whatman 903 ﬁlter paper (Whatman plc,
Maidstone, UK) to completely ﬁll the marked circles, correspond-
ing to a volume of 75–80 ml of whole blood.25 The ﬁlter papers
were left to air-dry overnight and were stored at 20 8C in plastic
ziplock dispensing bags with a silica desiccant (Elcon-Broker AS,
Holmestrand, Norway). Before transport to Norway, the DBS were
removed from the freezer and equilibrated at ambient temperature
for a minimum of 1 h. The old desiccants were replaced with new
ones before shipment at ambient temperature for up to 3 weeks.
2.3. CMV antibody in DBS eluates
One DBS from each individual was eluted in 500 ml 0.05%
phosphate-buffered saline (PBS)–Tween 20 solution, incubated for
6 h under gentle rotation at room temperature, and centrifuged at
10 000  g for 5 min. The supernatant was transferred to a sample
cup and kept at 4 8C overnight and subsequently tested for CMV
IgG by a commercial chemiluminescent microparticle immunoas-
say (CMIA; Architect, Abbott Laboratories, IL, USA) following the
manufacturer’s instructions. One CMV IgG positive and one
negative control sample were included in each run. CMV IgG <6
AU/ml was considered negative.
2.4. CMV PCR in DBS eluates
Total nucleic acids were extracted from one DBS from each
individual using the easyMAG (magnetic silica-based automatic
extraction) (bioMe´rieux, Inc., Durham, NC, USA) and the NucliSENS
easyMAG Extraction Kit with manual pre-treatment, in accordance
with the manufacturer’s recommendations for the processing of
DBS, with minor modiﬁcations.26 Brieﬂy, the spot was cut with
scissors, placed in 1100 ml of NucliSENS lysis buffer, and incubated
for 2 h under gentle rotation at room temperature. The supernatant
was clariﬁed by centrifugation at 250  g for 5 min, and 1000 mlwere subsequently transferred to the easyMAG platform (ﬁrmware
v3.0.5) running the on-board nucleic acid extraction protocol
(Generic v2.0.1). The elution volume was 50 ml, and 10 ml were
directly added to the PCR mix. Each eluate was run in duplicate
using the artus CMV TM PCR Kit (Qiagen) following the
manufacturer’s instructions. According to the manufacturer, this
PCR test has an analytical sensitivity of 200 copies/ml (95%
probability that 200 copies/ml will be detected). One positive
extraction control was included in each run. Quantitation
standards (1, 10, 100, 1000, and 10 000 CMV DNA copies/ml)
included in the supplied kit were used to generate a standard curve
in each run, allowing determination of the CMV viral load. The
average result of each duplicate eluate was used if both tested
positive; otherwise the result of the single positive eluate was
used. Calculation of the plasma volume contained in each DBS was
based on a mean hematocrit of 0.40 in the general population in
Haydom,27 i.e., approximately 48 ml plasma per DBS, and CMV
viremia in DBS eluates was expressed as copies/ml plasma.
CMV viral load in DBS eluates and EDTA plasma prepared in
parallel were tested for 11 patients with suspected CMV viremia at
the Renal Transplant Unit, Oslo University Hospital using the assay
in routine use at the laboratory for this purpose. DNA in plasma
was extracted by COBAS AmpliPrep (Roche Diagnostics, Basle,
Switzerland), and the CMV viral load was determined using the
Cobas Amplicor CMV Monitor Test (Roche Diagnostics) in
accordance with the manufacturer’s instructions. Samples
obtained from Quality Control for Molecular Diagnostics, Glasgow,
UK (QCMD) were used to standardize the quantiﬁcation of CMV
DNA in the specimens. Two samples were CMV viremia-negative
with both methods, whereas nine had detectable CMV viremia in
both plasma (median 5050, range 685–42 450 copies/ml) and DBS
(median 2406, range 61–100 172 copies/ml). The sample with the
lowest plasma CMV viral load (685 copies/ml) had detectable
viremia in only one of the corresponding duplicate DBS eluates (61
copies/ml). There was high correlation between viral load in
plasma and DBS (r = 0.87, p < 0.001). For viremic patients the
median DBS to plasma viremia ratio was 0.37. This difference was
not signiﬁcant (p = 0.26), but a trend for quantitative underesti-
mation of CMV viremia in DBS eluates was observed in the lower
range (Figure 1).
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Data are described with medians and interquartile ranges (IQR)
unless otherwise indicated. Non-parametric tests were used for
variables not conforming to the normal distribution, using Mann–
Whitney U-tests for group comparisons of continuous data and the
Wilcoxon signed rank test for related samples. Chi-square tests and
logistic regression were used to compare groups on categorical
data. Correlation between CMV viremia in plasma and DBS samples
was assessed by the Spearman rank coefﬁcient.
Survival probabilities for patients with CMV viremia were
presented by a Kaplan–Meier plot. Cox regression analysis was
used to calculate hazard ratios (HR) for mortality during the
follow-up period. All variables in the model were baseline
characteristics, except ART, which was treated as a time-
dependent variable in the multivariable Cox regression analysis.
Variables with a p-value of <0.20 in bivariate analysis were tested
sequentially using forward selection, retaining in the model only
those with a p-value of <0.05. WHO stage was not included in the
model, as this variable is closely related to other included variables,
i.e., fever, diarrhea, and body mass index (BMI). An alternative
multivariable Cox regression analysis was performed for patients
starting ART after baseline, assessing survival while on treatment,
by calculating HRs for mortality during the follow-up period.
Statistical signiﬁcance was deﬁned as p  0.05 (two-sided).
Statistical analyses were performed using IBM SPSS Statistics
version 19 for Windows (SPSS Inc., Chicago, IL, USA).Table 1
Baseline characteristics of 168 antiretroviral-naı¨ve patients according to the presence 
Characteristic Median (IQR) Total (%) 
Age group, years 36 (29–43)
<18 12 (7.1) 
18–39 94 (56.0) 
>39 62 (36.9) 
Sex
Female 118 (70.2) 
Male 50 (29.8) 
Pregnancy
Yes 15 (8.9) 
No 153 (91.1) 
BMI, kg/m2 19.0 (17.1–22.4)
<18.5 64 (38.1) 
18.5 87 (51.8) 
Missing 17 (10.1) 
CD4+ T cells, cells/mm3 205 (79–403)
<100 51 (30.4) 
100 114 (67.9) 
Missing 3 (1.8) 
Hemoglobin, g/dl 11.0 (9.5–12.4)
<11 76 (45.2) 
11 79 (47.0) 
Missing 13 (7.7) 
Fever
Yes 88 (52.4) 
No 76 (45.2) 
Missing 4 (2.4) 
Diarrhea
Yes 70 (41.7) 
No 94 (56.0) 
Missing 4 (2.4) 
WHO stage
1 15 (8.9) 
2 29 (17.3) 
3 40 (23.8) 
4 81 (48.2) 
Missing 3 (1.8) 
BMI, body mass index; CI, conﬁdence interval; CMV, cytomegalovirus; IQR, interquarti
a Trend.3. Results
3.1. Baseline characteristics of the study population in relation to CMV
viremia
The 168 ART-naı¨ve patients included in the study had
moderately advanced chronic HIV infections. The median baseline
CD4+ T cell count was 205 (IQR 79–403) cells/mm3. All patients
were CMV-seropositive in DBS eluates, with a median antibody
level of 62 (IQR 35–99) AU/ml.
A total of 38 patients (22.6%) had detectable CMV viremia
(median 118 (range 3–39 464) copies/ml) in at least one of two
duplicate DBS eluates.
Increasing CMV viral load was associated with a higher
probability of both duplicate eluates testing positive. In 14
patients (8.3%) with CMV viremia 200 copies/ml (median 711
(range 231–39 464) copies/ml), 27 of 28 (96.4%) duplicates were
positive in both eluates, consistent with a high detection rate for
samples in this range of measured viremia. Conversely, samples
from only seven of 24 patients (29.2%) with CMV <200 copies/ml
were positive in both eluates. According to the manufacturer, the
analytical sensitivity of the PCR test is 200 copies/ml. We therefore
deﬁned 200 CMV copies/ml as the threshold for viremia in the
survival analysis; baseline characteristics in relation to CMV
viremia 200 copies/ml are shown in Table 1.
Patients with CMV viremia 200 copies/ml had lower CD4+ T
cell counts than patients with lower or undetectable viremiaof a CMV viral load 200 copies/ml at baseline
CMV viremia 200 copies/ml
n (%) OR (95% CI) p-Value
0 (0.0)
9 (9.6)
5 (8.1) 1.2 (0.5–3.1)a 0.70a
12 (10.2) 2.7 (0.6–12.6) 0.20
2 (4.0) 1
1 (6.7) 0.8 (0.09–6.3) 0.81
13 (8.5) 1
9 (14.1) 3.4 (1.00–11.6) 0.05
4 (4.6) 1
1 (5.9)
11 (21.6) 10.2 (2.7–38.3) 0.001
3 (2.6) 1
0 (0.0)
10 (13.2) 3.8 (1.0–14.5) 0.05
3 (3.8) 1
1 (7.7)
13 (14.8) 13.0 (1.7–101.9) 0.02
1 (1.3) 1
0 (0.0)
9 (12.9) 2.6 (0.8–8.2) 0.10
5 (5.3) 1
0 (0.0)
0 (0.0)
1 (3.4)
0 (0.0)
13 (16.0) 4.7 (1.3–17.5)a 0.02a
0 (0.0)
le range; OR, odds ratio; WHO, World Health Organization.
Table 2
Clinical characteristics of patients with CD4+ T cell counts <100 cells/mm3 and CMV viremia 200 copies/ml
Patient
No.
Age Sex CMV viremia,
copies/ml
CD4+ T cell count,
baseline, cells/mm3
CD4+ T cell count,
last, cells/mm3
WHO
stage
Fever Diarrhea ART Died Clinical diagnoses
1 39 F 231 68a 68a 4 Yes Yes Yes Yes Wasting, cryptococcal meningitis,
tuberculosis
2 53 F 242 23a 23a 4 Yes No No Yes Wasting, tuberculosis,
Toxoplasma encephalitis
3 36 F 242 3 32 4 Yes Yes Yes Yes Wasting, tuberculosis
(abdominal mass)
4 23 F 288 63 762 4 Yes No Yes No Wasting, Kaposi’s sarcoma, tuberculosis
5 42 F 303 35a 35a 4 Yes Yes Yes Yes Wasting, tuberculosis, PCP
6 28 F 691 62a 62a 4 Yes Yes Yes Yes Wasting, severe fever, diarrhea
7 40 F 730 7a 7a 4 Yes Yes No Yes Wasting
8 30 M 1349 88 648 4 Yes No Yes No Wasting, tuberculosis
9 37 F 2010 46 338 4 Yes Yes Yes No Wasting
10 39 M 8365 55 129 2 No No Yes No Recurrent Herpes zoster
11 19 F 39 464 83 435 4 Yes Yes Yes No Wasting, cryptococcal meningitis,
tuberculosis
ART, antiretroviral therapy; F, female; M, male; PCP, Pneumocystis pneumonia.
a Only one CD4+ T cell count available.
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respectively; p < 0.001). Also, BMI was lower in the former group
(median 15.9 (IQR 15.4–19.7) and 19.2 (IQR 17.4–22.7), respec-
tively; p = 0.02).
In bivariate analysis, BMI <18.5 kg/m2, CD4+ T cell count <100
cells/mm3, hemoglobin <11 g/dl, fever, and WHO stage (including
WHO pediatric stage) were identiﬁed as signiﬁcant risk factors for
CMV viral load 200 copies/ml. There was no statistically
signiﬁcant overall difference in CD8+ T cell counts in the two
groups (data not shown).
3.2. Clinical manifestations in patients at high risk of CMV disease
At baseline, 51 patients (30.4%) had a CD4+ T cell count <100
cells/mm3, a level of immunodeﬁciency associated with an
increased risk of CMV disease. Eleven of these patients (21.6%)
also had CMV viremia 200 copies/ml, compared to three (2.6%)
with higher CD4+ T cell counts (p = 0.001).
Clinical characteristics of the 11 patients at the highest risk of
developing CMV disease, by having both a CD4+ T cell count <100
cells/mm3 and CMV viremia 200 copies/ml, are shown in Table 2.
At baseline 10 of these 11 patients (91%) had weight loss and fever
and were classiﬁed as WHO stage 4 due to wasting, and seven
(64%) reported diarrhea. Six patients (55%) died during follow-up.
All four patients with a CMV viral load >1000 copies/ml survived,
and all demonstrated a considerable increase in CD4+ T cell count
subsequent to ART. Presumptive diagnoses shown in Table 2 were
based on clinical and radiological examinations and direct
microscopy of sputum and cerebrospinal ﬂuid. Culture, PCR, and
histopathological examination of specimens for identiﬁcation of
infectious agents were not available. No cases of CMV retinitis,
including immune reconstitution inﬂammatory syndrome (IRIS),
or other CMV disease manifestations were observed.
3.3. CMV viremia as a predictor of survival
Thirty-three of the 168 patients (19.6%) were transferred to
other health centers or were lost to follow-up before the ﬁrst
scheduled follow-up visit, and these were excluded from the
survival analysis. CD4+ T cell counts tended to be higher in
excluded than in included individuals (median 327 (IQR 77–370)
and 160 (IQR 89–403) cells/mm3, respectively; p = 0.08). No
excluded patients had a CMV viral load 200 copies/ml. In
patients with a CMV viral load <200 copies/ml, the CD4+ T cellcounts in the excluded patients did not differ from the included
patients (median 207 (IQR 90–429) cells/mm3; p = 0.18).
The remaining 135 patients were followed to death or censoring
for up to 940 (median 465 (IQR 185–756)) days. One hundred
patients (74.1%) started ART after baseline. The median time to
start of ART was 35 (IQR 14–110) days. In total, 33 of 135 patients
(24.4%) died during the study period. The median time to death
was 54 (IQR 26–235) days. Compared to survivors, patients who
died had lower baseline CD4+ T cell counts (68 cells/mm3 (IQR 36–
155) vs. 243 (IQR 93–443); p < 0.001), lower hemoglobin (10.0 g/dl
(IQR 8.9–11.4) vs. 11.4 (IQR 9.7–13.0); p = 0.02), and lower BMI
(17.4 kg/m2 (IQR 15.9–19.6) vs. 19.0 (IQR 17.5–22.7); p = 0.01), and
a higher proportion of patients with CMV viremia 200 copies/ml
(eight of 33 (24.2%) vs. six of 102 (5.9%); p = 0.003).
The survival of patients according to the presence of CMV
viremia is shown as a Kaplan–Meier plot in Figure 2. There was no
signiﬁcant difference in survival between patients with undetect-
able viremia and detectable viremia <200 copies/ml, but a
signiﬁcantly increased risk of death in patients with CMV viremia
200 copies/ml compared to patients with lower and undetectable
viremia (p = 0.001).
Table 3 shows the results of the bivariate survival analysis.
Signiﬁcant risk factors for death included a BMI <18.5 kg/m2, CD4+
T cell count <100 cells/mm3, CMV viremia 200 copies/ml, a
history of fever, diarrhea, and WHO stage. In the multivariable Cox
survival analysis, CMV 200 copies/ml remained statistically
signiﬁcant with a HR of 5.0 (95% conﬁdence interval (CI) 2.1–11.9)
(p < 0.001) after adjusting for ART, BMI, hemoglobin, CD4+ T cell
count, fever, and diarrhea.
In an alternative multivariable Cox regression analysis restrict-
ed to 100 patients starting ART during follow-up and analyzing
survival while on treatment, CMV viremia 200 copies/ml
remained statistically signiﬁcant with a largely unchanged HR of
4.8 (95% CI 1.7–13.4) (p = 0.003) after adjusting for the same
variables as above, except ART.
Within the group of 14 patients with CMV viremia 200 copies/
ml, there was no signiﬁcant difference in the risk of death between
patients with high and low viral loads (data not shown).
4. Discussion
To our knowledge, this study is the ﬁrst to use DBS to assess
CMV seroprevalence and viremia in HIV-infected individuals. The
use of DBS for CMV detection is particularly relevant in developing
Figure 2. Kaplan–Meier plot of survival in patients with undetectable CMV viremia and detectable viremia at <200 and 200 copies/ml (n = 135). The ﬁgure shows that
survival was signiﬁcantly reduced in patients with CMV viremia 200 copies/ml compared to undetectable viremia and viremia <200 copies/ml.
Table 3
Bivariate analysis of baseline risk factors for death during follow-up of 135 HIV
patients
Risk factors Total (%) Mortality
No. of
deaths (%)
HR (95% CI) p-Value
Age group, years
<18 11 (8.1) 3 (27.3)
18–39 75 (55.6) 17 (22.7)
>39 49 (36.3) 13 (26.5) 1.2 (0.7–2.1)a 0.60a
Sex
Female 94 (69.6) 21 (22.3) 0.7 (0.3–1.3) 0.25
Male 41 (30.4) 12 (29.3) 1
Pregnancy
Yes 12 (8.9) 2 (16.7) 0.6 (0.2–2.7) 0.54
No 123 (91.1) 31 (25.2) 1
BMI, kg/m2
<18.5 53 (39.3) 19 (35.8) 2.7 (1.2–5.8) 0.01
18.5 68 (50.3) 10 (14.7) 1
Missing 14 (10.4) 4 (28.6)
Hemoglobin, g/dl
<11 65 (48.1) 20 (30.8) 2.0 (0.9–4.3) 0.08
11 62 (45.9) 10 (16.1) 1
Missing 8 (5.9) 3 (37.5)
CD4+ T cells, cells/mm3
<100 44 (32.6) 18 (40.9) 3.1 (1.5–6.2) 0.002
100 90 (66.7) 14 (15.6) 1
Missing 1 (0.7) 1 (100.0)
CMV viremia, copies/ml
<200 121 (89.6) 25 (20.7) 1
200 14 (10.4) 8 (57.1) 3.8 (1.7–8.4) 0.001
Fever
Yes 78 (57.8) 26 (33.3) 3.2 (1.4–7.4) 0.006
No 56 (41.5) 7 (12.5) 1
Missing 1 (0.7) 0 (0.0)
Diarrhea
Yes 61 (45.2) 20 (32.8) 2.1 (1.0–4.2) 0.04
No 73 (54.1) 13 (17.8) 1
Missing 1 (0.7) 0 (0.0)
WHO stage
1 15 (11.1) 0 (0.0)
2 18 (13.3) 0 (0.0)
3 30 (22.2) 5 (16.7)
4 70 (51.9) 28 (40.0) 4.1 (1.8–9.2)a 0.001a
Missing 2 (1.5) 0 (0.0)
BMI, body mass index; CI, conﬁdence interval; CMV, cytomegalovirus; HR, hazard
ratio; WHO, World Health Organization.
a Trend.
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hospitals and appropriate transportation and storage of liquid
blood samples is a challenge. Our study is also the ﬁrst to
demonstrate that CMV viremia is an independent risk factor for
death in an African population with access to ART. These results
suggest that CMV is a neglected cause of morbidity and mortality
in this part of the world.
All patients were CMV-seropositive in this population of
patients with moderately advanced chronic HIV infection in rural
Tanzania. Fourteen patients (8.3%) had CMV viremia 200 copies/
ml at baseline, and this group had a signiﬁcantly increased risk of
death when controlling for other risk factors. In patients with CD4+
T cell counts <100/mm3, a substantial proportion (21.6%) had CMV
viremia 200 copies/ml in DBS eluates. This combination of low
CD4+ T cell count and high CMV viral load deﬁnes a subgroup of
patients at particularly high risk of CMV disease. It has been
suggested that HIV-infected patients in resource-poor countries
tend to die from other opportunistic infections presenting at an
earlier stage of immunodeﬁciency, and that CMV disease
consequently may be rare.9,28,29 Our study indicates that CMV
disease may represent a clinical challenge even in rural Africa.
However, our data do not allow us to conclude whether the
observed increase in mortality in patients with CMV viremia was
due to undiagnosed CMV end-organ disease, CMV acting as a
cofactor of HIV disease progression, or CMV viremia acting as a
marker of disease severity.
CMV retinitis is the most common manifestation of CMV
disease in HIV-infected patients, and can be diagnosed by typical
ﬁndings on ophthalmoscopy, without the need for invasive or
sophisticated diagnostic tests.30 Although routine ophthalmosco-
py of patients with low CD4+ T cell counts was not performed in
our study population, patient ﬁles did not contain records of
progressively reduced vision compatible with CMV retinitis,
including IRIS, in any of the included individuals. Therefore,
undiagnosed serious CMV retinitis is unlikely in our study
population. It has been suggested that CMV retinitis may, for
unknown reasons, be less frequent in Africa than in Asian
developing countries, where CMV retinitis is common in severely
immunosuppressed HIV-infected individuals.30 Nevertheless, be-
fore ART was available, retinitis was reported from Africa in 0–8.5%
of HIV-infected individuals in cross-sectional studies,28 and in
21.4% in one prospective study from Togo.31
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contributed to morbidity and mortality in our study, as deﬁnite
diagnosis requires autopsy or histopathological examination of
biopsies, which was not available. However, the patients in our
cohort at highest risk of CMV disease, as deﬁned by CD4+ T cell
counts <100/mm3 and CMV viremia 200 copies/ml, had non-
speciﬁc symptoms and signs, including fever, diarrhea, meningitis,
cough, and confusion, that may have been due to CMV disease.
Other than causing end-organ disease, CMV can also act as a co-
factor for HIV progression in the absence of CMV disease.32 CMV is
a large virus that is controlled by a substantial fraction of the
cellular immune system. CD8+ CMV-speciﬁc T cells in blood may
comprise 10% of this subset in healthy individuals and up to 20% in
HIV-infected individuals on ART.33 Moreover, CMV has been
implicated as a signiﬁcant cause of immune activation in HIV
infection, which may speed up disease progression in HIV
infection.34
Methodologically, CMV DNA in DBS appears stable and robust
to degradation, even when stored at room temperature,35,36 and
our method showed good correlation with a validated commercial
assay for plasma samples. Some studies have found that peripheral
blood leukocytes and whole blood have a higher CMV viral load
than plasma,37,38 but one study found no difference in this
respect.39 Although DBS contain whole blood, our method tended
to underestimate viral load in DBS compared to plasma. In our
opinion, this is best explained by a lower yield of CMV DNA from
DBS. However, we assumed that the analytical sensitivity in the
tested DBS eluates was equal to other solutions containing CMV
DNA. The artus CMV TM PCR Kit (Qiagen) used for quantitation of
CMV viremia in DBS eluates has good numerical agreement and
superior analytical sensitivity in plasma compared with Cobas
Amplicor CMV Monitor,40 which is the established test in routine
clinical use at our laboratory. Therefore, differences in the
performance of these tests are unlikely to explain the lower
CMV viral load in DBS samples, observed particularly in the lower
range of viremia. Previous studies have demonstrated that the
detection of CMV viremia in DBS with a low viral load is
challenging. In one study of the capacity of 27 laboratories to
qualitatively detect CMV DNA, 91% of submitted datasets correctly
identiﬁed as CMV PCR-positive those samples with 8800 copies/ml
or higher, whereas only 12% correctly reported as positive a sample
containing 730 copies/ml.41 It is therefore likely that our analysis
of DBS eluates may have failed to detect some additional cases with
low-level viremia. However, this is unlikely to be of clinical
signiﬁcance for the identiﬁcation of patients at high risk of CMV
disease and death.
In general, it is difﬁcult to directly compare studies assessing
the prevalence of CMV viremia in HIV-infected individuals, due to
potential differences in CMV seroprevalence, degree of immuno-
deﬁciency, sampling techniques, and assays. In our study
population we found that 8.3% of patients had CMV viremia
200 copies/ml in DBS eluates. This is higher than reported in a
South African study where 5.2% of less immunosuppressed
individuals had CMV viremia >50 copies/ml in plasma samples,42
and considerably lower than in a Cambodian population where
42.4% of severely immunosuppressed individuals had >500
copies/ml in serum.15
To our knowledge, we are the ﬁrst to demonstrate that a high
CMV viral load is an independent risk factor for death in patients
with HIV infection in Africa even after the wide-scale implemen-
tation of ART. In the South African study, CMV viremia >1000
copies/ml was an independent predictor of death,42 and in the
Cambodian study the same was found for viremia >1300 (3.1 log)
copies/ml.15We found that a CMV viral load 200 copies/ml in DBS
eluates was a signiﬁcant independent risk factor for death, but the
lower threshold in our study may be explained at least in part bythe lower yield of CMV DNA in DBS eluates, with a median DBS to
plasma viremia ratio of 0.37.
Our study has some limitations. The lack of routine ophthal-
moscopy and histopathological tests for CMV disease has already
been discussed. Secondly, the participants were not tested for HIV
viral load, and we were therefore unable to adjust for this by
multivariable analysis. However, previous studies have generally
found CMV viremia to be associated with a worse prognosis, even
after controlling for HIV viremia.19–21 Third, 20% of the included
patients in the baseline cross-sectional study were excluded from
the survival analysis because of loss to follow-up. All excluded
patients had undetectable CMV viremia or a viral load <200 copies/
ml, and their CD4+ T cell counts were not statistically different
from included patients in this group. It is therefore likely that
excluded patients had a similar prognosis to included patients with
a CMV viral load <200 copies/ml. The excluded individuals are
therefore unlikely to be a source of selection bias in our estimate of
the HR for individuals with CMV 200 copies/ml. Finally, with only
14 patients with CMV viremia 200 copies/ml, the statistical
power for analysis within the group was low, and may explain why
we did not observe a higher risk of death with increasing CMV viral
load. In our study, the four patients with a viral load >1000 copies/
ml all survived, probably as a result of ART. Previous studies have
demonstrated that the risk of death increases with increasing viral
load above deﬁned thresholds.15,42
In conclusion, we found that DBS are suitable for the detection
of CMV viremia in developing countries. All patients were CMV-
seropositive, and a CMV viral load of potential clinical signiﬁcance
was frequent in ART-naı¨ve HIV-infected patients with low CD4+ T
cell counts in rural Tanzania. Despite subsequent ART, high-level
CMV viremia at baseline was associated with reduced survival.
Prospective studies are needed to determine if access to better
diagnostic tools and treatment of CMV could improve the
prognosis for HIV-infected individuals in developing countries.
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